Literature DB >> 33172554

[Clinical features of neuroblastoma: an analysis of 44 children].

Cheng-Guang Zhu1, Xiang-Ling He, Zhi-Ge Tang, Ke-Ke Chen, Run-Ying Zou, Xin Tian, Ya-Lan You.   

Abstract

OBJECTIVE: To study the clinical features of neuroblastoma (NB) and the factors influencing survival rate.
METHODS: A total of 44 children with NB who were admitted from April 2016 to February 2020 were enrolled as research subjects. A retrospective analysis was performed on their medical data and follow-up data.
RESULTS: The common clinical symptoms of these 44 children were fever (10/44, 23%), mass (9/44, 20%), abdominal pain (8/44, 18%), cough (7/44, 16%), pale complexion (3/44, 7%), claudication (2/44, 5%), and abnormal activity (2/44, 5%). According to the INSS stage, 2 children (4%) had stage I NB, 5 children (11%) had stage II NB, 5 children (11%) had stage III NB, and 32 children (73%) had stage IV NB. The mean follow-up time was (15.3±1.5) months, with a recurrence rate of 20% and an overall survival rate of 82%. Among the 44 children, 29 (66%) achieved event-free survival and 7 (16%) had survival with tumor. The univariate analysis showed that a pathological type of NB and an increase in serum neuron-specific enolase (NSE) decreased the overall survival rate of children with NB (P<0.05).
CONCLUSIONS: The clinical symptoms of children with NB are not specific at the first visit. Fever, abdominal pain, and mass are common symptoms, and there is a high proportion of children in the advanced stage. The pathological type of NB and an increase in serum NSE may be associated with a reduction in the overall survival rate of children with NB.

Entities:  

Year:  2020        PMID: 33172554      PMCID: PMC7666396     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  12 in total

1.  Prospective evaluation of the International Neuroblastoma Staging System (INSS) and the International Neuroblastoma Response Criteria (INRC) in a multicentre setting.

Authors:  V Castel; P García-Miguel; A Cañete; C Melero; A Navajas; J I Ruíz-Jiménez; S Navarro; M D Badal
Journal:  Eur J Cancer       Date:  1999-04       Impact factor: 9.162

2.  Outcomes After Radiation Therapy to Metastatic Sites in Patients With Stage 4 Neuroblastoma.

Authors:  Shravan Kandula; Roshan S Prabhu; Ronica Nanda; Jeffrey M Switchenko; Thomas Cash; Muna Qayed; Howard Katzenstein; Natia Esiashvili
Journal:  J Pediatr Hematol Oncol       Date:  2015-04       Impact factor: 1.289

3.  Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project.

Authors:  Holly J Meany; Wendy B London; Peter F Ambros; Katherine K Matthay; Tom Monclair; Thorsten Simon; Alberto Garaventa; Frank Berthold; Akira Nakagawara; Susan L Cohn; Andrew D J Pearson; Julie R Park
Journal:  Pediatr Blood Cancer       Date:  2014-07-07       Impact factor: 3.167

4.  The characteristics of mediastinal neuroblastoma.

Authors:  S Suita; T Tajiri; Y Sera; H Takamatsu; H Mizote; H Ohgami; N Kurosaki; T Hara; J Okamura; S Miyazaki; T Sugimoto; K Kawakami; M Tsuneyoshi; H Tasaka; H Yano; H Akiyama; K Ikeda
Journal:  Eur J Pediatr Surg       Date:  2000-12       Impact factor: 2.191

5.  Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.

Authors:  Cynthia S Kretschmar; Morris Kletzel; Kevin Murray; Paul Thorner; Vijay Joshi; Robert Marcus; E Ide Smith; Wendy B London; Robert Castleberry
Journal:  J Clin Oncol       Date:  2004-10-15       Impact factor: 44.544

6.  Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer.

Authors:  Nadia Howlader; Anne-Michelle Noone; Mandi Yu; Kathleen A Cronin
Journal:  Am J Epidemiol       Date:  2012-07-25       Impact factor: 4.897

Review 7.  Targeted Therapy for Neuroblastoma: ALK Inhibitors.

Authors:  J H Schulte; S Schulte; L C Heukamp; K Astrahantseff; H Stephan; M Fischer; A Schramm; A Eggert
Journal:  Klin Padiatr       Date:  2013-10-28       Impact factor: 1.349

8.  MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening.

Authors:  T Iehara; H Hosoi; K Akazawa; Y Matsumoto; K Yamamoto; S Suita; T Tajiri; T Kusafuka; E Hiyama; M Kaneko; F Sasaki; T Sugimoto; T Sawada
Journal:  Br J Cancer       Date:  2006-05-22       Impact factor: 7.640

Review 9.  High-Risk Neuroblastoma Treatment Review.

Authors:  Valeria Smith; Jennifer Foster
Journal:  Children (Basel)       Date:  2018-08-28

10.  The REST gene signature predicts drug sensitivity in neuroblastoma cell lines and is significantly associated with neuroblastoma tumor stage.

Authors:  Jianfeng Liang; Pan Tong; Wanni Zhao; Yaqiao Li; Li Zhang; Ying Xia; Yanbing Yu
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

View more
  1 in total

1.  [Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].

Authors:  Wei-Ling Liang; Xiao-Fan Ye; Gong Zhong; Jian-Jun Chen; Kang-Lin Dai; Ka Leung Daniel Cheuk; Shu Mo; Bo-Shen Wang; Chun-Yu Li; Xuan-Zhu Jiang; Zhi-Yuan Xu; Li Zhou; Irene Chan; Jian-Liang Chen; Patrick Chu; Pui Wah Pamela Lee; Chi Fung Godfrey Chan
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-07-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.